drugset / Trial / NCT05133193
Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate efficacy of a 14-day concomitant therapy for the third-line treatment of Helicobacter pylori infection, and whether it is safe while maintaining an ideal eradication rates.
Timeline
- Start
- 2021-11-20
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amoxicillin | Other / unclassified | — | — |
| Subject | Clarithromycin | Small molecule | — | — |
| Subject | Furazolidone | Small molecule | — | — |
| Subject | Levofloxacin | Small molecule | — | — |
| Subject | Metronidazole | Small molecule | — | — |
| Subject | Tetracycline | Unknown | — | — |
| Subject | Vonoprazan | Other / unclassified | — | — |
| Subject | tinidazole | Small molecule | — | — |